Audina M Berrocal1, Kenneth C Fan2, Hasenin Al-Khersan2, Catherin I Negron2, Timothy Murray3. 1. Department of Ophthalmology (A.M.B, K.C.F., H.A.-K., C.I.N.), Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida, USA. Electronic address: aberrocal@med.miami.edu. 2. Department of Ophthalmology (A.M.B, K.C.F., H.A.-K., C.I.N.), Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida, USA. 3. Murray Oncology and Retina (T.M.), South Miami, Florida, USA.
Abstract
PURPOSE: To focus on the longitudinal evaluation of high-risk infants for the development of retinopathy of prematurity (ROP) at a single tertiary neonatal intensive care unit (NICU), and to evaluate evolving demographics of ROP and the transition of treatment-warranted disease. DESIGN: Retrospective cohort study. METHODS: A consecutive retrospective review was performed of all infants screened for ROP between 1990 and 2019 at the Jackson Memorial Hospital neonatal intensive care unit. All inborn infants meeting a birth criteria of <32 weeks' gestational age (GA) or a birthweight (BW) of 1500 g were included. Longitudinal demographic, diagnostic, and treatment data were reported. RESULTS: Between January 1, 1990, and June 20, 2019, a total of 25,567 examinations were performed and 7436 patients were included. Longitudinal trends over 3 decades demonstrated a decreasing incidence of ROP (P < .05). Although the mean BW and GA increased over 3 decades, patients with ROP demonstrated lower BW and GA over time (P < .05). The prevalence of micro-premature infants (as defined by BW <750 g) continues to rise over time. Micro-preemies demonstrated increasing severity of zone and stage grading, plus disease, and propensity to require treatment (P < .05). The rate of progression of ROP to stage 4 and 5 disease has decreased over time, and there has been an associated increased adoption of intravitreal bevacizumab as primary and salvage therapy. CONCLUSIONS: Understanding the evolution of ROP infants and treatment over time is critical in identifying high-risk infants and in reducing the incidence of severe-stage ROP. Micro-prematurity is one of the significant risk factors for treatment-warranted ROP that continues to increase as neonatal care improves. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
PURPOSE: To focus on the longitudinal evaluation of high-risk infants for the development of retinopathy of prematurity (ROP) at a single tertiary neonatal intensive care unit (NICU), and to evaluate evolving demographics of ROP and the transition of treatment-warranted disease. DESIGN: Retrospective cohort study. METHODS: A consecutive retrospective review was performed of all infants screened for ROP between 1990 and 2019 at the Jackson Memorial Hospital neonatal intensive care unit. All inborn infants meeting a birth criteria of <32 weeks' gestational age (GA) or a birthweight (BW) of 1500 g were included. Longitudinal demographic, diagnostic, and treatment data were reported. RESULTS: Between January 1, 1990, and June 20, 2019, a total of 25,567 examinations were performed and 7436 patients were included. Longitudinal trends over 3 decades demonstrated a decreasing incidence of ROP (P < .05). Although the mean BW and GA increased over 3 decades, patients with ROP demonstrated lower BW and GA over time (P < .05). The prevalence of micro-premature infants (as defined by BW <750 g) continues to rise over time. Micro-preemies demonstrated increasing severity of zone and stage grading, plus disease, and propensity to require treatment (P < .05). The rate of progression of ROP to stage 4 and 5 disease has decreased over time, and there has been an associated increased adoption of intravitreal bevacizumab as primary and salvage therapy. CONCLUSIONS: Understanding the evolution of ROP infants and treatment over time is critical in identifying high-risk infants and in reducing the incidence of severe-stage ROP. Micro-prematurity is one of the significant risk factors for treatment-warranted ROP that continues to increase as neonatal care improves. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
Authors: Béatrice Blondel; Michael D Kogan; Greg R Alexander; Nirupa Dattani; Michael S Kramer; Alison Macfarlane; Shi Wu Wen Journal: Am J Public Health Date: 2002-08 Impact factor: 9.308
Authors: Jennifer L Simpson; Michele Melia; Michael B Yang; Angela N Buffenn; Michael F Chiang; Scott R Lambert Journal: Ophthalmology Date: 2012-03-03 Impact factor: 12.079
Authors: Jennifer L Jung; Brandie D Wagner; Emily A McCourt; Alan G Palestine; Ashlee Cerda; Jennifer H Cao; Robert W Enzenauer; Jasleen K Singh; Rebecca S Braverman; Erica Wymore; Anne M Lynch Journal: J AAPOS Date: 2017-05-12 Impact factor: 1.220